Epidermis

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

ULTRACLEAR, THE WORLD'S FIRST COLD FIBER LASER, WINS MAJOR BEAUTY AWARD FOR "BEST LASER TREATMENT FOR ALL SKIN TONES" -- SECOND YEAR IN A ROW

Retrieved on: 
Friday, March 29, 2024

The win in this highly regarded and very popular publication is a repeat favorite for the second year in a row, having secured the coveted award for UltraClear laser in 2023.

Key Points: 
  • The win in this highly regarded and very popular publication is a repeat favorite for the second year in a row, having secured the coveted award for UltraClear laser in 2023.
  • It vaporizes the outer layers of dull, damaged skin and heats the underlying skin layers with precisely controlled thermal energy.
  • This causes the skin to heal and restructure, growing new skin cells and increasing collagen and elastin production.
  • This recognition underscores the trust and confidence professionals can place in our technology to deliver exceptional results and advance patient care."

FORGET EVERYTHING YOU KNOW ABOUT MOISTURIZERS: INTRODUCING CLARINS MULTI-ACTIVE: A CUTTING-EDGE SOLUTION TO COMBAT STRESS-AGEING

Retrieved on: 
Wednesday, March 13, 2024

After years of research, Clarins Laboratories identified the detrimental effects of stress and fatigue on the skin, commonly referred to as stress-ageing1.

Key Points: 
  • After years of research, Clarins Laboratories identified the detrimental effects of stress and fatigue on the skin, commonly referred to as stress-ageing1.
  • Additionally, decreased fibroblast activity in the dermal layer results in diminished collagen and elastin production, essential for maintaining skin firmness.
  • To conclude, these two studies revealed how stress and lack of sleep visibly accentuate 8 signs of ageing2:
    1.
  • Clarins Multi-Active Line is available on www.clarins.com and at all official retailers, including Sephora, Ulta Beauty and Amazon.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.

Key Points: 
  • GentleView™ is a laser-based imaging device being developed to offer hybrid reflective confocal microscopy and photoacoustic imaging.
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • “SkinCure Oncology,” Brandt continued, “is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • “Our new devices, subject to FDA Clearance,” Brandt said, “will offer cutting-edge technology in line with SkinCure Oncology’s vision for the future of dermatology.

North America Canola oil Market Size, Share & Industry Trends Analysis Report, 2019-2022 and 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The "North America Canola oil Market Size, Share & Industry Trends Analysis Report By Nature (Conventional, and Organic), By Application (Food Processing, Food Service, Households, and Others), By Country and Growth Forecast, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Canola oil Market Size, Share & Industry Trends Analysis Report By Nature (Conventional, and Organic), By Application (Food Processing, Food Service, Households, and Others), By Country and Growth Forecast, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The North America Canola Oil Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
  • In the year 2019, the North America market's volume surged to 6,778.7 Kilo Tonnes, showcasing a growth of 2.7% (2019-2022).
  • The US region dominated the North America Canola Oil Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $6.8 Billion by 2030.

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Retrieved on: 
Thursday, March 7, 2024

Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.

Key Points: 
  • Reflective confocal microscopy, or RCM, will provide high resolution imaging of the epidermis, to a depth of 200 microns, for cellular level visualization of skin cancer lesions.
  • Brandt noted, "Mohs micrographic surgery has been the gold standard of care for the treatment of nonmelanoma skin cancer (NMSC) for more than 50 years.
  • "SkinCure Oncology," Brandt continued, "is helping dermatologists nationwide implement the GentleCure Experience – an advanced, noninvasive treatment for NMSC.
  • The new devices will feature technology for which SkinCure Oncology was recently awarded U.S. patent coverage.

CollPlant Issues Letter to Shareholders

Retrieved on: 
Thursday, February 15, 2024

Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.

Key Points: 
  • Our long-term collaboration with AbbVie to develop a paradigm-shifting regenerative dermal and soft tissue filler continues to advance.
  • In June of last year, we announced the achievement of an important milestone under this collaboration which triggered a $10 million payment from AbbVie to CollPlant.
  • Per CollPlant's agreement with AbbVie, CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on product sales.
  • In the second quarter of 2023, CollPlant hired a dedicated expert to lead our Environment, Social and Governance (ESG) effort.

Could protecting our proteins help us prevent ageing?

Retrieved on: 
Wednesday, February 7, 2024

This is Deinococcus radiodurans, one of the most resistant bacteria known to date, which lives in arid environments such as desert sand.

Key Points: 
  • This is Deinococcus radiodurans, one of the most resistant bacteria known to date, which lives in arid environments such as desert sand.
  • It can also overcome an irradiation dose 5,000 times greater than the lethal dose for humans.
  • Its DNA isn’t resistant, it’s simply repaired immediately by proteins that are indestructible in the face of this extreme radiation.
  • Hence the secret of the robustness of this extremophilic bacterium depends on the robustness of its “proteome” – the sum of all its proteins – and in particular its DNA repair proteins.

The keys to ageing

  • Numerous models have been proposed to explain the molecular basis of ageing, such as the theory of cellular senescence, the reduction in DNA repair capacity, telomere shortening, mitochondrial dysfunction and oxidative stress or chronic inflammation.
  • These different models all attempt to understand the consequences of ageing, not the causes.


Indeed, rather than focusing on our DNA and trying to protect it to slow down our ageing, what if we protected our proteome?

What is the proteome?

  • Proteins – from the Greek protos meaning “first” – are only exceeded as a constituent of the human body by water, and account for around 20% of its mass.
  • The term was coined by analogy with the genome: the proteome being to proteins what the genome is to genes, i.e.
  • the set of genes/proteins of an individual – this protein set varying according to the activity of the genes.


A structural role: many proteins are central to the maintenance and cohesion of our tissues. For example, actin and tubulin are involved in cell architecture. Keratin is involved in the architecture of our epidermis, hair and nails. Collagen is a protein that plays an important role in the structure of bones, cartilage and skin.
A functional role: enzymatic (for example, proteases are involved in cleaning up dysfunctional proteins and in desquamation), hormonal (for example, insulin regulates glycaemia), transport (for example, aquaporins transport water in the different layers of the skin) or defence (for example, immunoglobulins are involved in the immune response). All vital functions are thus ensured by the activity of proteins.

Carbonylation, the leading cause of irreparable damage to our proteome

  • It is under constant threat, because protein synthesis and degradation also depend on proteins.
  • Over time and as a result of external aggression, the proteome is subjected to various alterations, the most formidable of which is carbonylation, irreversible damage linked to the oxidation of proteins.
  • These carbonylated protein aggregates are found in most age-related diseases, as well as in the main signs of skin ageing.

Antioxidant chaperone molecules to act on the causes of ageing


To correctly perform their many jobs, proteins need to fold into a range of shapes and are helped out by specialised proteins called “chaperones”. These help out the proteins after their synthesis by ribosomes, or their correct folding after stress, such as heat.

  • In short, chaperones (protein or chemical) are the doctors of malformed proteins.
  • At the same time, their antioxidant effectiveness neutralises the causes of carbonylation.
  • In Deinococcus radiodurans, because its proteome is protected against oxidative damage by chaperone molecules, it remains intact and can then able to repair damage to its genome.


Miroslav Radman is founder and scientific director of the Mediterranean Institute for Life Sciences (MedILS). The MedILS has received funding from the NAOS company for several research collaborations. He is a consultant and member of the NAOS Scientific Committee.

Enspectra Health Announces US FDA Clearance of VIO‎™ System, First of Its Kind Technology to Visualize Skin Cellular Structures in Real-Time

Retrieved on: 
Wednesday, January 3, 2024

MOUNTAIN VIEW, Calif., Jan. 3, 2024 /PRNewswire/ -- Enspectra Health, a health tech company, announces US FDA 510(k) clearance of the VIO System, launching a new era in noninvasive imaging.

Key Points: 
  • MOUNTAIN VIEW, Calif., Jan. 3, 2024 /PRNewswire/ -- Enspectra Health, a health tech company, announces US FDA 510(k) clearance of the VIO System, launching a new era in noninvasive imaging.
  • VIO, the first of its kind technology, combines reflectance confocal and multiphoton microscopy to enable cellular resolution, cross-sectional imaging of skin in seconds.
  • Easily portable and handheld, VIO digitizes pathology directly from a patient's skin to provide clinical insights for physicians.
  • This is the first multiphoton imaging modality to ever be cleared by the FDA," said Gabriel Sanchez, Ph.D., CEO and co-founder of Enspectra Health.